跳至主要内容
临床试验/NCT02238431
NCT02238431撤回不适用

Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers: Reduces Time to Transfer and Cycle Cancellation

Antalya IVF1 个研究点 分布在 1 个国家开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
1
主要终点
Cycle cancellation

研究概览

简要总结

Currently all patients that have freeze-all ICSI treatment cycles have the start of their FET cycle scheduled with the use of OCP. While an excellent pregnancy rate (75%) for the patients that have a blastocyst transfer has been maintained over time, 15% of started FET cycles are being cancelled because of premature luteinization, and the treatment (to transfer) takes approximately 89 days. The use of a Lucrin depot may reduce the number of cycles cancelled and reduce the treatment time to approximately 69 days. The use of no drugs and allowing the normal menstrual cycle to determine the time to start the FET cycle may suit some patients. Whether these benefits can be obtained while still maintaining the current FET pregnancy rate will be the main focus of the trial.

详细描述

The patients will undergo standard assisted conception procedures; controlled ovarian stimulation (COS), oocyte pickup procedure (OPU), ICSI, embryo culture, blastocyst vitrification and frozen embryo transfer. If sufficient (>2) viable blastocyst develop from the in vitro culture of their embryos, all viable blastocysts will be cryopreserved using a routine vitrification procedure. This is the eligible patient population. On the day the last blastocyst(s) are frozen the patients will be given a further opportunity to ask questions and if satisfied they will be asked to complete a trial consent. At this point patients will be randomized by numeric code and given a schedule and drug prescription for scheduling the start of their hormone supplemented frozen embryo transfer cycle. During the scheduling period the patients will follow the drug prescription provided . After the completion of their treatment - the transfer of one or two vitrified-warmed blastocyst - the patients from both groups will receive identical luteal support drug schedules and prescriptions. A blood test will be performed on the 15th day of progesterone supplementation, to determine the βhCG blood concentration. Currently at Antalya IVF, approximately 75% of patients who have blastocysts transferred in a frozen embryo transfer cycle have a positive biochemical pregnancy test, >29 international units per litre (IU/L) of human chorionic gonadotropin (βhCG). If pregnant, patients will continue using estrogen and progesterone supplementation for a further 8 weeks. At 7 weeks of gestation (5 weeks after embryo transfer ) the patients will receive a transvaginal ultrasound scan (TVUS) to check for pregnancy viability (fetal sac with cardiac activity). Thereafter the patients will have regular TVUS to follow fetal development. At 20 weeks of gestation a TVUS will be performed to confirm an ongoing pregnancy (normal fetal development).

All drug packs are delivered to the clinic by the pharmacy after receiving the prescription. A staff member will verify the code on the prescription with randomization code allocated to the patient. The pack will then be given to the patient after verbally confirming patient identity. The packs will also contain a drug use instruction sheet and a trial information sheet.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
20 Years 至 42 Years(Adult)
性别
All
接受健康志愿者
是

入选标准

  • •If patients have >2 blastocysts vitrified

排除标准

  • •All patients not willing to participate in the study
  • •Patients with any known adverse reaction to one or the other of the drugs prescribed
  • •All patients that have no surviving blastocysts for transfer

研究组 & 干预措施

Natural, menstrual period

Experimental

to wait for the second bleed to commence the artificial FET cycle

干预措施: Natural (Other)

OCP active, artificial cycle start

Active Comparator

to take active OCP tablets (1 per day) from the 10th day following oocyte retrieval for at least 21 days

干预措施: OCP (Drug)

Lucrin depot, artificial cycle start

Experimental

intramuscular administration of Lucrin depot (half dose of 3.75mg) on the 5th day following oocyte retrieval

干预措施: Lucrin depot (Drug)

结局指标

主要结局

Cycle cancellation

时间窗: On day 14 of estrogen supplementation

blood progesterone concentration (\>2nmol/L) as a measure of premature luteinization

次要结局

  • Ongoing pregnancy rate(20 weeks of gestation)

研究者

发起方
Antalya IVF
申办方类型
Other
责任方
Principal Investigator
主要研究者

Kevin Coetzee

Scientific Advisor

Antalya IVF

研究点 (1)

Loading locations...

相似试验